Last reviewed · How we verify
Bedaquiline, Delamanid, Moxifloxacin
Bedaquiline, Delamanid, Moxifloxacin is a Antitubercular Small molecule drug developed by LigaChem Biosciences, Inc.. It is currently in Phase 2 development for Multidrug-resistant tuberculosis. Also known as: BDM.
Inhibits Mycobacterium tuberculosis ATP synthase
Inhibits Mycobacterium tuberculosis ATP synthase Used for Multidrug-resistant tuberculosis.
At a glance
| Generic name | Bedaquiline, Delamanid, Moxifloxacin |
|---|---|
| Also known as | BDM |
| Sponsor | LigaChem Biosciences, Inc. |
| Drug class | Antitubercular |
| Target | ATP synthase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
Bedaquiline inhibits the ATP synthase enzyme of Mycobacterium tuberculosis, leading to the disruption of the bacterial energy production and ultimately, cell death.
Approved indications
- Multidrug-resistant tuberculosis
Common side effects
- QT interval prolongation
- Hypotension
- Hypokalemia
Key clinical trials
- A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets (PHASE2)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
- Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB (PHASE2)
- Short-course Regimens for the Treatment of Pulmonary Tuberculosis (PHASE2, PHASE3)
- PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE) (PHASE2)
- Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis (PHASE2)
- A Study on the Short-course Treatment Regimen Containing Pretomanid for Drug-resistant Tuberculosis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bedaquiline, Delamanid, Moxifloxacin CI brief — competitive landscape report
- Bedaquiline, Delamanid, Moxifloxacin updates RSS · CI watch RSS
- LigaChem Biosciences, Inc. portfolio CI
Frequently asked questions about Bedaquiline, Delamanid, Moxifloxacin
What is Bedaquiline, Delamanid, Moxifloxacin?
How does Bedaquiline, Delamanid, Moxifloxacin work?
What is Bedaquiline, Delamanid, Moxifloxacin used for?
Who makes Bedaquiline, Delamanid, Moxifloxacin?
Is Bedaquiline, Delamanid, Moxifloxacin also known as anything else?
What drug class is Bedaquiline, Delamanid, Moxifloxacin in?
What development phase is Bedaquiline, Delamanid, Moxifloxacin in?
What are the side effects of Bedaquiline, Delamanid, Moxifloxacin?
What does Bedaquiline, Delamanid, Moxifloxacin target?
Related
- Drug class: All Antitubercular drugs
- Target: All drugs targeting ATP synthase
- Manufacturer: LigaChem Biosciences, Inc. — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Multidrug-resistant tuberculosis
- Also known as: BDM
- Compare: Bedaquiline, Delamanid, Moxifloxacin vs similar drugs
- Pricing: Bedaquiline, Delamanid, Moxifloxacin cost, discount & access